Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

被引:36
|
作者
Paillé, V
Brachet, P
Damier, P
机构
[1] CHU Nantes, INSERM, U437, F-44093 Nantes, France
[2] CHU Nantes, Neurol Clin, F-44035 Nantes 01, France
[3] CHU Nantes, Ctr Invest Clin, F-44035 Nantes 01, France
关键词
behavior; dyskinesias; levodopa; 6-OHDA; Parkinson's disease;
D O I
10.1097/00001756-200403010-00035
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias. We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
引用
收藏
页码:561 / 564
页数:4
相关论文
共 50 条
  • [1] Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
    Paille, Vincent
    Henry, Vincent
    Lescaudron, Laurent
    Brachet, Philippe
    Damier, Philippe
    MOVEMENT DISORDERS, 2007, 22 (04) : 533 - 539
  • [2] Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease
    Marin, C.
    Bonastre, M.
    Mengod, G.
    Cortes, R.
    Rodriguez-Oroz, M. C.
    Obeso, J. A.
    EXPERIMENTAL NEUROLOGY, 2013, 250 : 304 - 312
  • [3] Incidence of dyskinesias in levodopa-treated Parkinson's disease
    Zaborowska, Marzena
    Maciejek, Zdzislaw
    Wawrzyniak, Slawomir
    AKTUALNOSCI NEUROLOGICZNE, 2012, 12 (01): : 40 - 43
  • [4] Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
    Metman, LV
    Del Dotto, P
    van den Munckhof, P
    Fang, J
    Mouradian, MM
    Chase, TN
    NERVENHEILKUNDE, 1998, 17 (10) : 480 - 484
  • [5] Therapy for dyskinesias in Parkinson's disease patients
    Stefani, Alessandro
    Pierantozzi, Mariangela
    Koch, Giacomo
    Galati, Salvatore
    Stanzione, Paolo
    FUTURE NEUROLOGY, 2010, 5 (02) : 277 - 299
  • [6] (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease
    Ekesbo, A
    Andren, PE
    Gunne, LM
    Tedroff, J
    NEUROREPORT, 1997, 8 (11) : 2567 - 2570
  • [7] Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias
    Alam, Mesbah
    Rumpel, Regina
    Jin, Xingxing
    von Wrangel, Christof
    Tschirner, Sarah K.
    Krauss, Joachim K.
    Grothe, Claudia
    Ratzka, Andreas
    Schwabe, Kerstin
    EXPERIMENTAL NEUROLOGY, 2017, 294 : 19 - 31
  • [8] Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model
    David J. Brooks
    Wiener klinische Wochenschrift, 2006, 118 : 570 - 572
  • [9] Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease
    Duan, WM
    Rodrigures, CMP
    Zhao, LR
    Steer, CJ
    Low, WC
    CELL TRANSPLANTATION, 2002, 11 (03) : 195 - 205
  • [10] Effect of Cdk5 Antagonist on L-Dopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease
    Guan, Qiang
    Liu, Xueyuan
    He, Yusheng
    Jin, Lingjing
    Zhao, Lijuan
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (06) : 421 - 427